vs
Side-by-side financial comparison of DIODES INC (DIOD) and HAEMONETICS CORP (HAE). Click either name above to swap in a different company.
DIODES INC is the larger business by last-quarter revenue ($391.6M vs $346.4M, roughly 1.1× HAEMONETICS CORP). HAEMONETICS CORP runs the higher net margin — 28.1% vs 2.6%, a 25.5% gap on every dollar of revenue. On growth, DIODES INC posted the faster year-over-year revenue change (15.4% vs 4.8%). HAEMONETICS CORP produced more free cash flow last quarter ($209.9M vs $12.4M). Over the past eight quarters, DIODES INC's revenue compounded faster (13.9% CAGR vs 1.5%).
Diodes Incorporated is a global semiconductor manufacturer that designs, produces and supplies discrete, analog and mixed-signal semiconductor products. Its solutions serve key end markets including automotive, industrial, consumer electronics, personal computing and communications infrastructure, with a worldwide customer base.
Haemonetics Corporation is a global provider of blood and plasma supplies and services. The company was founded in Natick, Massachusetts by Dr. Allen (Jack) Latham in the 1970s.
DIOD vs HAE — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2026
| Metric | | |
|---|---|---|
| Revenue | $391.6M | $346.4M |
| Net Profit | $10.2M | $97.3M |
| Gross Margin | 31.1% | 57.2% |
| Operating Margin | 3.4% | 36.1% |
| Net Margin | 2.6% | 28.1% |
| Revenue YoY | 15.4% | 4.8% |
| Net Profit YoY | 23.8% | — |
| EPS (diluted) | $0.23 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $346.4M | ||
| Q4 25 | $391.6M | $339.0M | ||
| Q3 25 | $392.2M | $327.3M | ||
| Q2 25 | $366.2M | $321.4M | ||
| Q1 25 | $332.1M | $330.6M | ||
| Q4 24 | $339.3M | $348.5M | ||
| Q3 24 | $350.1M | $345.5M | ||
| Q2 24 | $319.8M | $336.2M |
| Q1 26 | — | $97.3M | ||
| Q4 25 | $10.2M | $44.7M | ||
| Q3 25 | $14.3M | $38.7M | ||
| Q2 25 | $46.1M | $34.0M | ||
| Q1 25 | $-4.4M | $58.0M | ||
| Q4 24 | $8.2M | $37.5M | ||
| Q3 24 | $13.7M | $33.8M | ||
| Q2 24 | $8.0M | $38.4M |
| Q1 26 | — | 57.2% | ||
| Q4 25 | 31.1% | 59.7% | ||
| Q3 25 | 30.7% | 59.5% | ||
| Q2 25 | 31.5% | 59.8% | ||
| Q1 25 | 31.5% | 58.4% | ||
| Q4 24 | 32.7% | 55.5% | ||
| Q3 24 | 33.7% | 54.2% | ||
| Q2 24 | 33.6% | 52.0% |
| Q1 26 | — | 36.1% | ||
| Q4 25 | 3.4% | 19.9% | ||
| Q3 25 | 3.0% | 17.9% | ||
| Q2 25 | 2.6% | 16.8% | ||
| Q1 25 | 0.4% | 21.6% | ||
| Q4 24 | 3.5% | 16.9% | ||
| Q3 24 | 6.2% | 15.0% | ||
| Q2 24 | 1.2% | 11.8% |
| Q1 26 | — | 28.1% | ||
| Q4 25 | 2.6% | 13.2% | ||
| Q3 25 | 3.6% | 11.8% | ||
| Q2 25 | 12.6% | 10.6% | ||
| Q1 25 | -1.3% | 17.5% | ||
| Q4 24 | 2.4% | 10.8% | ||
| Q3 24 | 3.9% | 9.8% | ||
| Q2 24 | 2.5% | 11.4% |
| Q1 26 | — | — | ||
| Q4 25 | $0.23 | $0.95 | ||
| Q3 25 | $0.31 | $0.81 | ||
| Q2 25 | $0.99 | $0.70 | ||
| Q1 25 | $-0.10 | $1.17 | ||
| Q4 24 | $0.18 | $0.74 | ||
| Q3 24 | $0.30 | $0.66 | ||
| Q2 24 | $0.17 | $0.74 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $377.0M | $245.4M |
| Total DebtLower is stronger | $25.7M | $1.2B |
| Stockholders' EquityBook value | $1.9B | $796.3M |
| Total Assets | $2.4B | $2.4B |
| Debt / EquityLower = less leverage | 0.01× | 1.53× |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $245.4M | ||
| Q4 25 | $377.0M | $363.4M | ||
| Q3 25 | $386.4M | $296.4M | ||
| Q2 25 | $327.3M | $292.9M | ||
| Q1 25 | $343.9M | $306.8M | ||
| Q4 24 | $316.1M | $320.8M | ||
| Q3 24 | $319.3M | $299.3M | ||
| Q2 24 | $273.9M | $344.4M |
| Q1 26 | — | $1.2B | ||
| Q4 25 | $25.7M | $1.2B | ||
| Q3 25 | $24.9M | $1.2B | ||
| Q2 25 | $26.4M | $1.2B | ||
| Q1 25 | $20.5M | $1.2B | ||
| Q4 24 | $20.7M | — | ||
| Q3 24 | $22.2M | — | ||
| Q2 24 | $20.3M | — |
| Q1 26 | — | $796.3M | ||
| Q4 25 | $1.9B | $911.5M | ||
| Q3 25 | $1.9B | $849.2M | ||
| Q2 25 | $1.9B | $882.3M | ||
| Q1 25 | $1.8B | $820.8M | ||
| Q4 24 | $1.8B | $906.9M | ||
| Q3 24 | $1.8B | $878.9M | ||
| Q2 24 | $1.8B | $905.4M |
| Q1 26 | — | $2.4B | ||
| Q4 25 | $2.4B | $2.5B | ||
| Q3 25 | $2.5B | $2.4B | ||
| Q2 25 | $2.5B | $2.5B | ||
| Q1 25 | $2.4B | $2.5B | ||
| Q4 24 | $2.4B | $2.5B | ||
| Q3 24 | $2.4B | $2.5B | ||
| Q2 24 | $2.4B | $2.5B |
| Q1 26 | — | 1.53× | ||
| Q4 25 | 0.01× | 1.34× | ||
| Q3 25 | 0.01× | 1.44× | ||
| Q2 25 | 0.01× | 1.39× | ||
| Q1 25 | 0.01× | 1.49× | ||
| Q4 24 | 0.01× | — | ||
| Q3 24 | 0.01× | — | ||
| Q2 24 | 0.01× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $38.1M | $293.2M |
| Free Cash FlowOCF − Capex | $12.4M | $209.9M |
| FCF MarginFCF / Revenue | 3.2% | 60.6% |
| Capex IntensityCapex / Revenue | 6.6% | 9.5% |
| Cash ConversionOCF / Net Profit | 3.74× | 3.01× |
| TTM Free Cash FlowTrailing 4 quarters | $137.2M | $417.1M |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $293.2M | ||
| Q4 25 | $38.1M | $93.6M | ||
| Q3 25 | $79.1M | $111.3M | ||
| Q2 25 | $41.5M | $17.4M | ||
| Q1 25 | $56.7M | $116.6M | ||
| Q4 24 | $81.8M | $43.8M | ||
| Q3 24 | $54.4M | $48.8M | ||
| Q2 24 | $14.4M | $-27.4M |
| Q1 26 | — | $209.9M | ||
| Q4 25 | $12.4M | $87.2M | ||
| Q3 25 | $62.8M | $106.3M | ||
| Q2 25 | $21.1M | $13.6M | ||
| Q1 25 | $40.8M | $100.9M | ||
| Q4 24 | $62.1M | $35.2M | ||
| Q3 24 | $39.4M | $39.4M | ||
| Q2 24 | $-3.5M | $-33.1M |
| Q1 26 | — | 60.6% | ||
| Q4 25 | 3.2% | 25.7% | ||
| Q3 25 | 16.0% | 32.5% | ||
| Q2 25 | 5.8% | 4.2% | ||
| Q1 25 | 12.3% | 30.5% | ||
| Q4 24 | 18.3% | 10.1% | ||
| Q3 24 | 11.2% | 11.4% | ||
| Q2 24 | -1.1% | -9.8% |
| Q1 26 | — | 9.5% | ||
| Q4 25 | 6.6% | 1.9% | ||
| Q3 25 | 4.2% | 1.5% | ||
| Q2 25 | 5.6% | 1.2% | ||
| Q1 25 | 4.8% | 4.7% | ||
| Q4 24 | 5.8% | 2.5% | ||
| Q3 24 | 4.3% | 2.7% | ||
| Q2 24 | 5.6% | 1.7% |
| Q1 26 | — | 3.01× | ||
| Q4 25 | 3.74× | 2.09× | ||
| Q3 25 | 5.54× | 2.88× | ||
| Q2 25 | 0.90× | 0.51× | ||
| Q1 25 | — | 2.01× | ||
| Q4 24 | 9.93× | 1.17× | ||
| Q3 24 | 3.95× | 1.44× | ||
| Q2 24 | 1.80× | -0.71× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
DIOD
| Distributor | $253.1M | 65% |
| Direct Sales | $138.5M | 35% |
HAE
| Hospital | $159.6M | 46% |
| Plasma | $130.3M | 38% |
| Blood Center | $56.4M | 16% |
